• Skip to WISTA Sites
  • Skip to Main menu
  • Skip to Page content
WISTA Logo
  • WISTA
  • WISTA.Plan
  • WISTA.Service
  • Adlershof
  • Charlottenburg
  • South West
  • Marzahn
WISTA direkt
Search
  • de
  • en
  • WISTA Logo
  • About
    • Mission / Management
      • Company Profile
      • Team
      • Boards
      • Annual Reports
      • Invitations to tender
    • Sustainability / Diversity
    • Subsidiaries
    • Directions
  • News / Press
    • Overview
    • News
    • Events / Calendar
      • Diversity Conference Adlershof
    • Social Media Wall
    • Press
    • Magazine "Potenzial"
    • Adlershof Journal
    • Downloads
  • Services
    • All WISTA services
    • Business programmes
      • Adlershof Founder's Lab
    • Networks / Cooperations
    • Talent promotion / Recruiting
    • Event and Visitors Service
  • Projects
    • Focus Topics
    • Team Innovation
  • Sites
    • Overview
    • Technology Park Adlershof
    • Innovation Centre CHIC Charlottenburg
    • Innovation Campus FUBIC South West
    • CleanTech Business Park Marzahn
    • Business Office “Zukunftsorte”
  • Real Estate
    • Current Real Estate Offers
    • ST3AM Working Environments
    • Facility Management
  • Talents
    • Overview
    • WISTA as Employer
      • Jobs
    • WISTA Academy
      • Overview
    • Talent Promotion / Training
  • WISTA
  • WISTA.Plan
  • WISTA.Service
  • Adlershof
  • Charlottenburg
  • South West
  • Marzahn
WISTA direkt

News / Press

  • Overview
  • News
  • Events / Calendar
  • Social Media Wall
  • Press
  • Magazine "Potenzial"
  • Adlershof Journal
  • Downloads
  • Editorial Staff
  • WISTA
  • News / Press
06. May 2011

Homing Pharmaceuticals

Patients with degenerative or inflammatory eye diseases may now hope for a cure

Adlershof Special: TheraKine BioDelivery is working to place medical agents precisely at the focus of the inflammation.
TheraKine BioDelivery is working to place medical agents precisely at the focus of the inflammation.

The Adlershof biotech company TheraKine BioDelivery GmbH is working on the targeted delivery of agents to the focus of infl ammation. Compared with the usual methods, the chances of a cure are greater, and there are considerably fewer side effects.

The diagnosis of an eye disease like diabetic retinopathy or age related macular degeneration (AMD) comes as a shock: the deteriorating eyesight often leads to complete blindness. The standard therapies can at best slow down the process, however at the price of serious side effects like haemorrhaging in the eye, cataracts, and retinal damage.

A more gentle treatment with chances of a cure is the promise made by TheraKine BioDelivery (TKBD) GmbH, which was founded in October 2009 and operates to a certain extent as a development laboratory for the US firm TheraKine. “At the Adlershof location, all innovations were conceived, realised, and subjected to preclinical tests,” explained Dr Andreas Voigt, Chief Scientist at TKBD. His tools are therapeutic proteins. “What interests us are above all the antibodies, a special class of protein that forms the foundation of natural immune defence,” he explained. These antibodies are encapsulated with a method developed by TheraKine and transported precisely to the focus of inflammation in the eye where they gradually bring their effects to bear. Experts speak of “drug delivery”, a fiddly affair because the antibodies must be packaged in approved pharmaceutical substances that first release them at the right place in the eye. “And only there,” stressed Voigt. For the body, on the other hand, this packaging must degrade compatibly and free of side effects. Experiments in the laboratory and on animals have shown that this works.

The advantages of this form of administration are obvious: considerably less agent needs to be applied, with dramatic reductions in side effects and savings in costs. Moreover, the patient is spared the discomfort of repeated medical injections directly into the eye. Voigt estimates that in about five years millions of people with chronically inflammatory and degenerative eye diseases will benefit from initial applications.

by Chris Löwer

Link: www.therakine.com

  • LinkedInshare0
  • Facebookshare0
  • WhatsAppshare0
  • E-Mail
  • © WISTA Management GmbH
  • Legal Notice
  • Privacy Policy
  • Contact
  • Career
  • Press
  • Social Media Guide
Member of:
Zukunftsorte Logo